Breaking Ground: From CPAP Treatment to the First Medicine for OSA Patients with Obesity

被引:1
|
作者
Lisik, Daniil [1 ,2 ]
Zou, Ding [2 ]
机构
[1] Univ Gothenburg, Inst Med, Sahlgrenska Acad, Krefting Res Ctr, S-40530 Gothenburg, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Sleep & Vigilance Disorders, Medicinaregatan 8B,Box 421, S-40530 Gothenburg, Sweden
关键词
Drug treatment; GLP-1 receptor agonist; Obstructive sleep apnea; Phenotype; Precision medicine; Treatable trait; OBSTRUCTIVE SLEEP-APNEA; POSITIVE AIRWAY PRESSURE; EXCESSIVE DAYTIME SLEEPINESS; ORAL APPLIANCE; HEALTH OUTCOMES; WEIGHT-LOSS; LOOP GAIN; THERAPY; ACETAZOLAMIDE; ADHERENCE;
D O I
10.1007/s13665-024-00365-w
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of Review Pharmacologic alternatives in management of obstructive sleep apnea (OSA) have been pursued for decades. Considering rapid development and promising findings in recent years, we provide an overview of novel agents and treatment targets, ongoing trials, as well as future perspectives.Recent Findings Several drugs demonstrate efficacy, though none is sufficient to cure the disease as a monotherapy. Instead, the main potential lies in applying drug therapy in specific subgroups or as an addition to established treatments (e.g., positive airway pressure, oral appliance therapy). Glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists may be particularly beneficial in obese OSA patients. As a major breakthrough, terzipatide, a GIP analog and GLP-1 receptor agonist, has become the first FDA-approved and EMA-sanctioned pharmacologic treatment option of OSA in obese individuals. Beyond this, alerting drugs could help manage residual daytime sleepiness and improve daytime functioning. However, long-term studies on safety, adherence, and effectiveness are scarce and highlight certain limitations and challenges.Summary Incorporating pharmaceuticals along conventional OSA management may provide synergy benefit in certain patients, but side-effects and risk reduction of related adverse outcomes over time is yet to be assessed. Furthermore, guidelines/frameworks for mapping out applicable treatment targets are needed.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Treatment of early undiagnosed airflow obstruction in patients of OSA on CPAP improves sleep quality and symptoms
    Kulkarni, Tarang
    Chakraborty, Sovan Kanti
    Dhar, Raja
    Sovani, Milind
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [42] CPAP treatment on depression and anxiety symptoms in OSA patients: a SAVE study and meta-analysis
    Zheng, D.
    Xu, Y.
    Yu, S.
    Hackett, M.
    Woodman, R.
    Li, Q.
    Woodman, M.
    Loffler, K.
    Rodgers, A.
    Drager, L. F.
    Lorenzi-Filho, G.
    Wang, X.
    Tripathi, M.
    Mediano, O.
    Ou, Q.
    Chen, R.
    Liu, Z.
    Zhang, X.
    Luo, Y.
    McArdle, N.
    Mukherjee, S.
    McEvoy, R. D.
    Anderson, C. S.
    JOURNAL OF SLEEP RESEARCH, 2019, 28
  • [43] Analysis of the myoelectric characteristics of genioglossus in REM sleep and its improvement by CPAP treatment in OSA patients
    Yingqian Zhou
    Di Zhao
    Guoping Yin
    Jingjing Li
    Xin Cao
    Yuhuan Zhang
    Jingying Ye
    Sleep and Breathing, 2020, 24 : 471 - 482
  • [44] Experiences with CPAP treatment in patients with obstructive sleep apnea syndrome and obesity
    Willman, Maria
    Igelstrom, Helena
    Martin, Cathrin
    Asenlof, Pernilla
    EUROPEAN JOURNAL OF PHYSIOTHERAPY, 2012, 14 (04) : 166 - 174
  • [45] ARTERIAL NOREPINEPHRINE AND EPINEPHRINE LEVELS IN PATIENTS WITH OSA ARE NOT ALTERED ACUTELY BY TREATMENT WITH OXYGEN OR NASAL-CPAP
    REMSBURG, S
    GARPESTAD, E
    LAHIVE, K
    WEISS, JW
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (04): : A1015 - A1015
  • [46] Transition from APAP to CPAP may be a cost-effective health intervention in OSA patients
    Alves, Adelaide
    Gigante, Ana Rita
    Machado, Daniela
    Sanches, Ines
    Marcoa, Raquel
    Franco, Ines
    Monteiro, Regina
    Nogueira, Carla
    Ferreira, Daniela
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2021, 47 (06)
  • [47] EFFECT OF SHORT TERM CPAP TREATMENT ON BLOOD PRESSURE IN PATIENTS WITH HYPERTENSION AND MODERATE-TO-SEVERE OSA
    Hornstrup, Bodil
    Gjorup, Pia
    Wessels, Jost
    Lauridsen, Thomas
    Pedersen, Erling
    Bech, Jesper
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [48] Depression, physical activity, energy consumption, and quality of life in OSA patients before and after CPAP treatment
    C. Diamanti
    E. Manali
    M. Ginieri-Coccossis
    K. Vougas
    K. Cholidou
    E. Markozannes
    P. Bakakos
    I. Liappas
    M. Alchanatis
    Sleep and Breathing, 2013, 17 : 1159 - 1168
  • [49] CPAP Improves Endothelial Function In Patients With Minimally Symptomatic OSA: Results From The Mosaic Trial
    Kohler, M.
    Craig, S.
    Pepperell, J.
    Nicoll, D.
    Bratton, D.
    Nunn, A.
    Leeson, P.
    Davies, R. J. O.
    Stradling, J. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [50] CPAP IMPROVES ENDOTHELIAL FUNCTION IN MINIMALLY SYMPTOMATIC OSA PATIENTS: RESULTS FROM THE MOSAIC TRIAL
    Kohler, M.
    Craig, S. E.
    Pepperell, J. C. T.
    Nicoll, D.
    Bratton, D.
    Nunn, A.
    Davies, R. J. O.
    Stradling, J. R.
    THORAX, 2010, 65 : A9 - A10